ASTROCYTOMA, IDH-MUTANT, GRADE 2
Clinical trials for ASTROCYTOMA, IDH-MUTANT, GRADE 2 explained in plain language.
Never miss a new study
Get alerted when new ASTROCYTOMA, IDH-MUTANT, GRADE 2 trials appear
Sign up with your email to follow new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for brain tumor patients
Disease control OngoingThis early-stage trial tests a new drug (telaglenastat) combined with standard radiation and chemotherapy for people with a specific type of brain tumor (IDH-mutated astrocytoma). The main goal is to find the safest dose and check for side effects in about 40 participants. The dr…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 2
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:06 UTC
-
Experimental drug combo targets recurrent brain cancer
Disease control TerminatedThis early-stage trial tests the safety and best dose of a drug called triapine when given with radiation therapy for people whose glioblastoma or astrocytoma has come back. Triapine works by blocking enzymes that help cancer cells grow, while radiation uses high-energy beams to …
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 2
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:01 UTC